Dreaming under antidepressants: A systematic review on evidence in depressive patients and healthy volunteers

• Published in: Sleep medicine reviews Vol. 17; no. 2; pp. 133 - 142
• Main Authors: Tribl, Gotthard G, Wetter, Thomas C, Schredl, Michael
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2013
• Subjects: Antidepressants; Antidepressive Agents - pharmacology; Antidepressive Agents - therapeutic use; Antidepressive Agents, Tricyclic - pharmacology; Antidepressive Agents, Tricyclic - therapeutic use; Depression; Depressive Disorder - drug therapy; Depressive Disorder - physiopathology; Dream content; Dream recall; Dreams - drug effects; Humans; Monoamine Oxidase Inhibitors - pharmacology; Monoamine Oxidase Inhibitors - therapeutic use; Neurology; Nightmares; REM sleep behavior disorder; Serotonin Uptake Inhibitors - pharmacology; Serotonin Uptake Inhibitors - therapeutic use; Sleep Medicine; post-traumatic stress disorder; AD; Nightmares; antidepressant; serotonin norepinephrine reuptake inhibitor; Depression; Dream content; international classification of sleep disorders, revised; rapid eye movement; REM sleep behavior disorder; dream recall frequency; PTSD; SSRI; Dream recall; selective serotonin reuptake inhibitor; SNRI; Antidepressants; RBD; ICSD-R; DRF; REM
• ISSN: 1087-0792; 1532-2955
• DOI: 10.1016/j.smrv.2012.05.001

Summary Sleep related symptoms of depression include sleep fragmentation, early morning awakening, decreased rapid eye movement (REM) sleep latency, increased REM density, and more negative dream content. Most tricyclic antidepressants (ADs) increase total sleep time and decrease wake time after sleep onset, while many selective serotonin reuptake inhibitors (SSRIs) have an opposite effect. However, almost all ADs prolong REM sleep latency and reduce the amount of REM sleep. Case reports and research data indicate a strong effect of ADs on dream recall and dream content. We performed a systematic review (1950 to August 2010) about ADs impact on dreaming in depressive patients and healthy volunteers. Twenty-one clinical studies and 25 case reports were eligible for review and document a clear AD effect on dreaming. The major finding, both in depressed patients and in healthy volunteers, is a decrease of dream recall frequency (DRF) under ADs. This is a rather consistent effect in tricyclic ADs and phenelzine, less consistently documented also for SSRIs/serotonin norepinephrine reuptake inhibitors (SNRIs). Tricyclic ADs induce more positive dream emotions. Withdrawal from tricyclic ADs and from the monoamine oxidase inhibitors phenelzine and tranylcypromine may cause nightmares. Intake and even more withdrawal of SSRIs/SNRIs seem to intensify dreaming, which may be experienced in different ways; a potential to cause nightmares has to be taken into account. Though there are clear-cut pharmacological effects of ADs on DRF and dream content, publications have been surprisingly scarce during the past 60 years. There is evidence of a gap in neuropsychopharmacological research. AD effects on dreams should be recognized and may be used in treatment.